drug
(cilastatin sodium + imipenem + relebactam)
Marketedupdated 5mo agoby $MRK Merck & Co., Inc.
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 1 investigational indication.
all catalysts(3)
approval · 3
Jul 16, 2019
approval
$MRK148.87+0.06%
RECARBRIO (CILASTATIN SODIUM) — FDA approval
(cilastatin sodium + imipenem + relebactam)
→
Jun 4, 2020
approval
$MRK148.87+0.06%
RECARBRIO (CILASTATIN SODIUM) — FDA approval
(cilastatin sodium + imipenem + relebactam)
→
Dec 9, 2025
approval
$MRK148.87+0.06%
RECARBRIO (CILASTATIN SODIUM) — FDA approval
(cilastatin sodium + imipenem + relebactam)
→
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 9, 2028
~2.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (1)
- Mar 21, 2033compositionUS 8487093
FDA exclusivities (3)
- Jul 16, 2029GAINGAIN Antibiotic (5y)2.8y
- Dec 9, 2028NPPNew Product (3y)2.2y
- Jul 16, 2024NCENew Chemical Entity (5y)
News(1)
- STAT+: Merck discontinues a crucial antibiotic despite concerns over superbug resistanceMerck discontinued Recarbio, an important antibiotic in the U.S., despite concerns over resistance to superbugs.stat · 22h ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that